Market Overview:
The global clinical nutrition for cancer care market size is expected to reach USD 7.11 billion by 2032, exhibiting the CAGR of 4.9% during the forecast period.
Cancer is created when some unusual cells in the body evolve in an uninhabited manner. A substantial escalation has been witnessed in the pervasiveness of cancer lately due to several probabilities, such as desk-bound lifestyle, family history, genetic illnesses, and environmental subjection. The clinical nutrition for cancer care market size is expanding as the elements, such as the capacity to lessen the probability of malnutrition and enhance the treatment results, are proliferating the demand for nutritional reinforcement commodities, thus pushing the growth of the market.
Market Overview
Prominent enhancements in cancer cures have been acquired over the past decades due to multimodal therapies causing enhanced rates of cure and extended existence in the palliative setup. The healthcare systems will encounter notable escalation in the aggregate of patients, particularly the elder ones. The appropriateness and the consequence of a multimodal cure viewpoint relies on several elements, the most crucial being nutrition, in spite of the fact that the treatment duration is curative or palliative. Thus, the acquisition of relevant capabilities in clinical nutrition and cross-functional team proceedings is important in order that all medicos and healthcare experts can offer maximum nutrition as an amalgamated part of cancer cure.
Leading Players
The market is integrated in nature. A handful of firms collectively account for notable market share owing to elements such as commodity portfolios of nutritional supplements and improved undeviating and deviating existence globally. A list of key companies profiled in the clinical nutrition for cancer care market are:
- Abbott Nutrition (U.S.)
- Baxter (U.S.)
- Bayer AG (Germany)
- Danone Nutricia (The Netherlands)
- GlaxoSmithKline plc (UK)
- Medtrition, Inc. (U.S.)
- Nestlé Health Science (Switzerland)
- Otsuka Holdings Co., Ltd. (Japan)
- Pfizer Inc. (U.S.)
- Victus, Inc. (U.S.)
Regional Overview:
This section of the research report provides an analysis of the geographic landscape of the Clinical Nutrition For Cancer Care Market. It covers several aspects like industry share, gross margin and growth rate for all the major regions of the industry. By going through the regional analysis section, businesses can better understand the needs and wants of their target market. Also, it enables companies to make informed decisions about the products or services they’re providing. Furthermore, the research report provides an in-depth analysis of all the major sub-regions for a comprehensive understanding of the market.
Clinical Nutrition for Cancer Care, Regional Outlook (Revenue – USD Billion, 2019-2032)
- North America
- Type Outlook
- Oral Nutrition
- Parenteral Nutrition
- Enteral Feeding Formulas
Cancer Type Outlook
- Head & Neck Cancer
- Stomach & Gastrointestinal Cancers
- Blood Cancer
- Breast Cancer
- Lung Cancer
- Others
- Age Group Outlook
- Adult
- Paediatric
- Sales Channel Outlook
- Offline
- Online
- Type Outlook
- Europe
- Type Outlook
- Oral Nutrition
- Parenteral Nutrition
- Enteral Feeding Formulas
Cancer Type Outlook
- Head & Neck Cancer
- Stomach & Gastrointestinal Cancers
- Blood Cancer
- Breast Cancer
- Lung Cancer
- Others
- Age Group Outlook
- Adult
- Paediatric
- Sales Channel Outlook
- Offline
- Online
- Type Outlook
Recent Developments:
- Nestlé Health Science – Oral Impact Su Yi Su (July 2022)
Nestlé Health Science launched Oral Impact Su Yi Su, China’s first Foods for Special Medical Purpose (FSMP), aimed at supporting patients suffering from tumor conditions.- Approved as a dietary supplement for individuals with specific medical needs, focusing on improving nutritional intake for those dealing with the effects of cancer and related treatments.
- This product is a part of Nestlé’s commitment to offering specialized nutrition solutions for managing complex health conditions.
The ability of nutritional support products to improve the immunity of cancer patients by providing the required amount of nutrients is primarily responsible for the market growth. Moreover, the implementation of strategic initiatives such as new product launches, merges, acquisitions, alliance, and partnerships contribute to the market growth. For instance, in January 2024, Danone Nutricia announced a new partnership with Resilience to develop nutritional support module for patients with cancer. Such strategic initiatives will make nutrition an integral part of oncology treatment in the coming years.